Please login to the form below

Not currently logged in
Email:
Password:

gabapentin enacarbil

This page shows the latest gabapentin enacarbil news and features for those working in and with pharma, biotech and healthcare.

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’s restless legs syndrome treatment Horizant

In its notice, the US regulator said GSK is “experiencing a backorder situation”, leaving an expected shortage of Horizant (gabapentin enacarbil) until June 2013 – one month after XenoPort assumes responsibility for

Latest news

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

  • GSK Restless Legs Syndrome drug approved

    GlaxoSmithKline (GSK) and XenoPort have won marketing approval from the US Food and Drug Administration (FDA) for Horizant (gabapentin enacarbil), a non-dopaminergic treatment for moderate-to-severe primary Restless Legs ... The drug, which was

  • GSK migraine study fails

    The drug, gabapentin enacarbil (GSK1838262/XP13512), is a new chemical entity that provides dose-proportional, sustained exposure of gabapentin using high-capacity transport mechanisms in the gastrointestinal tract.

  • FDA rejects GSK and Xenoport's Horizant

    GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Gabapentin enacarbil is also being developed in partnership with Astellas Pharma for the potential treatment of Restless Legs

  • Deals in development

    Xenoport can expect upwards of USD 640m from GlaxoSmithKline for its phase III restless legs syndrome candidate, gabapentin enacarbil. ... Restless legs syndrome. gabapentin enacarbil. Anacor Pharmaceuticals. Schering-Plough. > 625m. Onychomycosis.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics